Skip to page content
Office of Workers' Compensation Programs
Bookmark and Share

Division of Energy Employees Occupational Illness Compensation (DEEOIC)

Special Exposure Cohort Employees (SEC)

The Energy Employees Occupational Illness Compensation Program Act established a Special Exposure Cohort (SEC) for certain classes of employees. The SEC allows eligible claimants to be compensated without the completion of a NIOSH radiation dose reconstruction or determination of the probability of causation. To qualify for compensation as a member of an SEC class, a covered employee must have at least one of the 22 specified cancers and worked for a specified period of time at one of the SEC work sites. The statutory SEC classes describe employees who:

  • worked at gaseous diffusion plants in Paducah, Kentucky, Portsmouth, Ohio, or Oak Ridge, Tennessee for a total of at least 250 days before February 1, 1992, and were monitored for radiation exposure with dosimetry badges or had jobs with similar exposures to those monitored.
  • worked before January 1, 1974, on Amchitka Island, Alaska and were exposed to radiation related to the Long Shot, Milrow or Cannikin underground nuclear tests.

The Act also authorizes the Secretary of Health and Human Services to add other classes of employees to the SEC. The following additional classes of employees have been added to the SEC. Click on the link for a site listed below to see details on each designation:

Allied Chemical Corporation

Ames Laboratory

Area IV of the Santa Susana Field Laboratory

Baker Brothers

Battelle Laboratories King Avenue

Bethlehem Steel Corporation

Blockson Chemical Company

Brookhaven National Laboratory

BWX Technologies, Inc.

Canoga Avenue

Clarksville Modification Center

Clinton Engineer Works

Combustion Engineering

Connecticut Aircraft Nuclear Engine Laboratory (CANEL)

DeSoto Avenue

Dow Chemical Company

Downey Facility

Electro Metallurgical

Feed Material Production Center (Fernald)

General Atomics

General Electric Co.

Grand Junction Operations Office

Hanford

Harshaw Harvard-Denison

Hood Building

Horizons, Inc.

Iowa Ordnance Plant (Iowa Army Ammunition Plant), Line 1

Joslyn Manufacturing and Supply Co.

Kellex/Pierpont

Lake Ontario Ordnance Works (LOOW)

Lawrence Berkeley National Laboratory

Lawrence Livermore National Laboratory

Linde Ceramics

Los Alamos National Laboratory

Mallinckrodt Chemical Works

Medina Modification Center

Metallurgical Laboratory

Metals and Controls Corp.

Mound

Nevada Test Site

Norton Company

Nuclear Materials and Equipment Corporation (NUMEC), Park Township

Nuclear Materials and Equipment Corporation (NUMEC), Apollo

Nuclear Metals, Inc,

Oak Ridge Hospital

Oak Ridge Institute for Nuclear Studies Cancer Research Hospital (ORINS)

Oak Ridge National Laboratory (X-10)

Pacific Proving Grounds

Pantex

Piqua Organic Moderated Reactor Site

Revere Copper and Brass

Rocky Flats

S-50 Oak Ridge Thermal Diffusion Plant

SAM (Special Alloyed or Substitute Alloy Materials) Laboratories of Columbia University

Sandia National Laboratories

Sandia National Laboratories-Livermore

Savannah River

Simonds Saw and Steel Company

Spencer Chemical Company/Jayhawk Works

Standard Oil Development Company

St. Louis Airport Storage

Texas City Chemicals, Inc.

Tyson Valley Powder Farm

University of Rochester Atomic Energy Project

Ventron Corporation

Vitro Manufacturing

Wah Chang

Westinghouse Atomic Power Development Plant

Westinghouse Electric Corp.

Winchester Engineering and Analytical Center

W.R. Grace, Erwin, Tennessee

W.R. Grace, Curtis Bay, Maryland

Y-12

These employees, or their survivors, from any of the above listed facilities, are eligible for benefits if, after beginning covered employment, they contracted one or more of the following specified cancers:

(1)    Leukemia, if onset of the disease occurred at least two years after first exposure.  (Chronic lymphocytic leukemia (CLL) is excluded.)

(2)    Primary or secondary lung cancer, including sarcoma of the lung (other than in situ lung cancer that is discovered during or after a post-mortem exam).

(3)    Primary or secondary bone cancer (including the bone form of solitary plasmacytoma, myelodysplastic syndrome, myelofibrosis with myeloid metaplasia, essential thrombocytosis or essential thrombocythemia, primary polycythemia vera [also called polycythemia rubra vera, P. vera, primary polycythemia, proliferative polycythemia, spent-phase polycythemia, or primary erythremia], and chondrosarcoma of the cricoid cartilage of the larynx).

(4)    Primary or secondary renal cancer

(5)    The following diseases, provided onset was at least five years after the first exposure:

(i)     Multiple myeloma;

(ii)    Lymphomas (other than Hodgkin’s disease);

(iii)   Primary cancer of the:

(A)      thyroid

(B)      male or female breast

(C)      esophagus

(D)      stomach

(E)      pharynx (including the soft palate, back of the mouth, base of the tongue, tonsils, and larynx)

(F)      small intestine

(G)      pancreas

(H)      bile ducts

(I)       gall bladder

(J)       salivary gland

(K)      urinary bladder (including ureter and urethra)

(L)      brain (malignancies only, not including intracranial endocrine glands and other parts of the central nervous system)

(M)     colon (including rectum)

(N)      ovary (including fallopian tubes)

(O)      liver (except if cirrhosis or hepatitis B is indicated)